+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Therapy Market by RNA Type, Delivery System, Therapeutic Modality, Application Area, End User - Global Forecast 2026-2032- Product Image
RNA Therapy Market by RNA Type, Delivery System, Therapeutic Modality, Application Area, End User - Global Forecast 2026-2032- Product Image
Sale

RNA Therapy Market by RNA Type, Delivery System, Therapeutic Modality, Application Area, End User - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968964
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The RNA Therapy Market is projected to reach USD 13.71 Billion in 2026. It is expected to continue growing at a CAGR of 8.71%, reaching USD 22.68 Billion by 2032.

RNA therapy has moved from a specialized scientific platform into a core modality for modern biopharmaceutical development. The field spans messenger RNA therapeutics, small interfering RNA drugs, antisense oligonucleotides, RNA interference therapies, aptamers, and guide RNA-enabled gene editing approaches. Validated approvals, including nusinersen for spinal muscular atrophy, patisiran for hereditary transthyretin-mediated amyloidosis, inclisiran for LDL-C reduction, and mRNA vaccines for COVID-19, demonstrate that RNA-based medicines can deliver clinically meaningful outcomes across rare diseases, infectious diseases, cardiometabolic disorders, and oncology.

The RNA therapy market is being shaped by advances in lipid nanoparticles, GalNAc conjugation, chemically modified nucleotides, scalable synthesis, and improved analytical characterization. Industry attention is increasingly focused on delivery beyond the liver, durability of response, repeat dosing safety, cold-chain optimization, and regulatory readiness for platform-based product families. For decision-makers, RNA therapeutics represent both a high-growth innovation segment and a complex operating environment requiring disciplined evidence generation, manufacturing resilience, and differentiated clinical strategy.

Transformative Shifts in the RNA Therapy Landscape

The RNA therapy landscape is undergoing a structural shift from single-product innovation toward programmable medicine platforms. The success of mRNA vaccines accelerated investment in RNA design, formulation, and manufacturing infrastructure, while approved siRNA and antisense therapies validated chronic and rare disease applications. Developers are now expanding from hepatic targets into muscle, central nervous system, lung, immune, and tumor microenvironment delivery, where tissue specificity remains a central competitive differentiator.

Another major shift is the convergence of RNA therapeutics with precision medicine. Biomarker-defined populations, genetic diagnostics, newborn screening, and companion testing are improving patient identification for RNA-based interventions. At the same time, regulatory agencies are increasingly familiar with oligonucleotide chemistry, platform comparability, and manufacturing controls, creating a more mature path for developers that can demonstrate quality, safety, and reproducible clinical benefit.

Cumulative Impact of Artificial Intelligence on RNA Therapy

Artificial intelligence is increasingly influencing RNA therapy discovery, design, and development. AI-enabled models support target prioritization, off-target risk assessment, sequence optimization, codon usage design, immune-stimulation prediction, and lipid nanoparticle formulation screening. The FDA has reported a sharp rise in drug and biologic submissions containing AI or machine learning components, signaling that computational approaches are becoming embedded in regulated development workflows.

The cumulative impact of AI is most visible in cycle-time compression and experiment prioritization rather than in replacing biological validation. For RNA therapeutics, AI can help narrow candidate libraries, improve manufacturability, identify toxicity signals earlier, and integrate multi-omics evidence for patient stratification. Industry leaders that combine AI with high-quality wet-lab data, traceable model governance, and regulatory documentation are better positioned to improve probability of success while maintaining scientific credibility.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a leading hub for RNA therapy innovation, supported by the United States biotechnology ecosystem, FDA experience with mRNA vaccines, siRNA drugs, antisense oligonucleotides, and advanced therapy regulatory pathways. Canada contributes through academic research, clinical trial participation, public genomics initiatives, and health system infrastructure, while Mexico is increasingly relevant for regional healthcare access discussions, clinical operations, and cross-border supply-chain planning.

Europe benefits from the European Medicines Agency, the Horizon Europe research framework, national genomics strategies, and strong biomanufacturing clusters across Germany, France, the United Kingdom, Italy, and Spain. Asia-Pacific is expanding through China’s large clinical trial base, Japan’s mature regulatory and pharmaceutical environment, South Korea’s biologics manufacturing strength, India’s cost-efficient scientific talent and vaccine production experience, and Australia’s active early-stage clinical research incentives. Latin America, led by Brazil and Mexico, is gaining attention for infectious disease experience, diverse patient recruitment, and public health networks, while the Middle East and Africa are emerging through vaccine access programs, genomics initiatives, healthcare modernization, and gradual investments in local biomanufacturing capacity.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN countries are building relevance in RNA therapy through expanding clinical research networks, vaccine manufacturing ambitions, and public health preparedness programs. Singapore plays a regional role in biomedical R&D and advanced manufacturing, while Thailand, Malaysia, Indonesia, the Philippines, and Vietnam offer growing patient access and trial-enrollment potential when regulatory alignment, pharmacovigilance, reimbursement readiness, and cold-chain capacity are addressed.

The European Union provides harmonized regulatory pathways, cross-border research funding, data protection rules, and strong intellectual property structures that support RNA therapeutic development. GCC countries are investing in precision medicine, genomics, tertiary care, and pharmaceutical localization as part of economic diversification strategies. BRICS nations are important for scientific and patient scale, with China and India offering large research and manufacturing bases, Brazil and South Africa contributing regional access and public health perspectives, and Russia maintaining scientific capacity amid external constraints. G7 markets remain central to premium reimbursement, advanced clinical adoption, regulatory precedent, and post-approval evidence generation, while NATO member countries overlap substantially with high-income biopharma markets and resilient medical supply-chain priorities.

Key Country Insights for RNA Therapy Growth

The United States leads RNA therapy commercialization through deep venture capital markets, FDA-approved RNA medicines, advanced clinical trial infrastructure, and a dense network of biotech developers, contract manufacturers, and academic centers. Canada supports translational research, genomics, and clinical collaboration, while Mexico is an important North American market for patient access and regional healthcare partnerships. Brazil anchors Latin America with a large population, established clinical research capacity, and public health experience relevant to vaccine and infectious disease platforms.

In Europe, the United Kingdom, Germany, and France are prominent in RNA research, regulatory science, and pharmaceutical development, while Italy and Spain strengthen clinical trial networks, specialist hospitals, and hospital-based adoption. Russia maintains scientific expertise but faces geopolitical, regulatory, and supply-chain constraints. In Asia-Pacific, China is scaling RNA research, clinical development, and manufacturing; India offers scientific talent, vaccine infrastructure, and cost-efficient production potential; Japan provides mature regulatory and pharmaceutical capabilities; Australia is recognized for early-phase clinical research and favorable trial operations; and South Korea is advancing biologics manufacturing, vaccine platforms, and global CDMO relevance.

Actionable Recommendations for RNA Therapy Industry Leaders

Industry leaders should prioritize delivery innovation, because tissue targeting remains the most important technical constraint for RNA therapy expansion beyond liver-directed programs. Investment in lipid nanoparticle engineering, ligand conjugation, endosomal escape technologies, and local delivery approaches should be paired with rigorous safety pharmacology, biodistribution studies, immunogenicity assessment, and repeat-dose monitoring.

Organizations should also strengthen CMC strategy early. Scalable oligonucleotide synthesis, impurity control, analytical comparability, sterile fill-finish capacity, raw material security, and cold-chain resilience can determine development timelines as much as clinical efficacy. Organizations should build regulatory engagement plans that address platform data, immunogenicity, repeat dosing, pharmacovigilance, and long-term follow-up. Partnerships with diagnostics providers, AI-enabled discovery platforms, CDMOs, and regional clinical networks can accelerate development while reducing risk.

Research Methodology

This executive summary is developed through secondary research and expert synthesis of publicly available, verifiable sources, including regulatory approvals and guidance from the FDA and EMA, clinical trial registries, peer-reviewed literature, public health agency updates, patent databases, and recognized biotechnology industry disclosures. The analysis emphasizes confirmed product approvals, documented platform advances, regional policy signals, and observable investment and manufacturing trends.

The methodology applies triangulation across regulatory, scientific, commercial, and geographic datasets to identify durable market patterns rather than speculative claims. Each insight is assessed for relevance to RNA therapeutics, including mRNA therapy, siRNA drugs, antisense oligonucleotides, RNA interference, delivery systems, GMP manufacturing, clinical adoption, and regional access dynamics. The resulting perspective is designed to support planning, market positioning, and digital communication.

Conclusion

RNA therapy is now an established and expanding therapeutic category, supported by approved medicines, validated delivery technologies, and increasing regulatory familiarity. The sector’s next phase will depend on expanding delivery to new tissues, improving durability and tolerability, reducing manufacturing complexity, and demonstrating value in large and genetically defined patient populations.

Organizations that combine strong science, platform governance, AI-enabled development, regional access planning, and manufacturing excellence will be best positioned to compete. As RNA therapeutics continue to reshape rare disease, infectious disease, oncology, neurology, and cardiometabolic care, the market offers substantial opportunity for developers capable of converting programmable biology into reliable, accessible, and clinically differentiated medicines.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. RNA Therapy Market, by RNA Type
7.1. Messenger RNA
7.1.1. Circular mRNA
7.1.2. Conventional mRNA
7.2. Small Interfering RNA
7.2.1. Unmodified siRNA
7.2.2. Chemically Modified siRNA
7.3. Antisense Oligonucleotides
7.4. MicroRNA
7.5. Ribozymes
8. RNA Therapy Market, by Delivery System
8.1. Exosomes
8.2. Lipid Nanoparticles
8.3. Polymer Carriers
8.4. Viral Vectors
9. RNA Therapy Market, by Therapeutic Modality
9.1. Gene Silencing
9.2. Gene Replacement
9.3. Protein Expression Induction
9.4. Splicing Modulation
9.5. Immune System Modulation
10. RNA Therapy Market, by Application Area
10.1. Cardiovascular Diseases
10.2. Genetic Disorders
10.3. Infectious Diseases
10.3.1. Bacterial Infections
10.3.2. Viral Infections
10.4. Metabolic Disorders
10.5. Neurological Disorders
10.6. Oncology
10.6.1. Hematological Malignancies
10.6.2. Solid Tumors
10.7. Rare Diseases
10.7.1. Gaucher Disease
10.7.2. Neuromuscular Disorders
10.7.3. Sickle Cell Disease
11. RNA Therapy Market, by End User
11.1. Biotechnology Companies
11.2. Hospitals & Clinics
11.3. Pharmaceutical Companies
11.4. Research Institutes
12. Asia-Pacific RNA Therapy Market
13. Europe RNA Therapy Market
14. North America RNA Therapy Market
15. Latin America RNA Therapy Market
16. Africa RNA Therapy Market
17. Middle East RNA Therapy Market
18. NATO RNA Therapy Market
19. G7 RNA Therapy Market
20. European Union RNA Therapy Market
21. BRICS RNA Therapy Market
22. ASEAN RNA Therapy Market
23. GCC RNA Therapy Market
24. United States RNA Therapy Market
25. China RNA Therapy Market
26. Germany RNA Therapy Market
27. Japan RNA Therapy Market
28. India RNA Therapy Market
29. United Kingdom RNA Therapy Market
30. France RNA Therapy Market
31. Canada RNA Therapy Market
32. Italy RNA Therapy Market
33. Australia RNA Therapy Market
34. South Korea RNA Therapy Market
35. Brazil RNA Therapy Market
36. Mexico RNA Therapy Market
37. Russia RNA Therapy Market
38. Spain RNA Therapy Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Alnylam Pharmaceuticals, Inc.
40.2. Arbutus Biopharma Corporation
40.3. Arrowhead Pharmaceuticals, Inc.
40.4. AstraZeneca PLC
40.5. Benitec Biopharma Limited
40.6. Biogen Inc.
40.7. BioNTech SE
40.8. Cartesian Therapeutics, Inc.
40.9. Cenix BioScience GmbH
40.10. Deep Genomics
40.11. Eli Lilly and Company
40.12. F. Hoffmann-La Roche Ltd
40.13. GSK PLC
40.14. Ionis Pharmaceuticals, Inc.
40.15. MiNA Therapeutics Limited
40.16. Moderna, Inc.
40.17. NeuBase Therapeutics, Inc.
40.18. Nordic Nanovector ASA
40.19. Novartis AG
40.20. Novo Nordisk A/S
40.21. Nutcracker Therapeutics, Inc.
40.22. Pfizer Inc.
40.23. ProQR Therapeutics N.V.
40.24. Sanofi S.A.
40.25. Silence Therapeutics PLC
40.26. Sirnaomics, Inc.
40.27. Suzhou Abogen Biosciences Co., Ltd.
40.28. Triplet Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL RNA THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RNA THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RNA THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RNA THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL RNA THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST RNA THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC RNA THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. GERMANY RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. JAPAN RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. INDIA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. AUSTRALIA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. BRAZIL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. MEXICO RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL RNA THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL RNA THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MESSENGER RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MESSENGER RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MESSENGER RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CIRCULAR MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CIRCULAR MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CIRCULAR MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SMALL INTERFERING RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SMALL INTERFERING RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SMALL INTERFERING RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL UNMODIFIED SIRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL UNMODIFIED SIRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL UNMODIFIED SIRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHEMICALLY MODIFIED SIRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CHEMICALLY MODIFIED SIRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CHEMICALLY MODIFIED SIRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RIBOZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RIBOZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RIBOZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL POLYMER CARRIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL POLYMER CARRIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL POLYMER CARRIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENE SILENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENE SILENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENE SILENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GENE REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GENE REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GENE REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PROTEIN EXPRESSION INDUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PROTEIN EXPRESSION INDUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PROTEIN EXPRESSION INDUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SPLICING MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SPLICING MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SPLICING MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GAUCHER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GAUCHER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GAUCHER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL SICKLE CELL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPE RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 135. EUROPE RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 136. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 137. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 138. EUROPE RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 139. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 140. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 141. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 142. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. AFRICA RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. AFRICA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 167. AFRICA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 168. AFRICA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 169. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 170. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 171. AFRICA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 172. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 173. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 174. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 175. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST RNA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. NATO RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 188. NATO RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 189. NATO RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 190. NATO RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 191. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 192. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 193. NATO RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 194. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 195. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 196. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 197. NATO RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. G7 RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 199. G7 RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 200. G7 RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 201. G7 RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 202. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 203. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 204. G7 RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 205. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 206. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 207. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 208. G7 RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. BRICS RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 221. BRICS RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 222. BRICS RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 223. BRICS RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 224. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 225. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 226. BRICS RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 227. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 228. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 229. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 230. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. ASEAN RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 232. ASEAN RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 233. ASEAN RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 234. ASEAN RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 235. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 236. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 237. ASEAN RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 238. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 239. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 240. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 241. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. GCC RNA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 243. GCC RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 244. GCC RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 245. GCC RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 246. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 247. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 248. GCC RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 249. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 250. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 251. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 252. GCC RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. CHINA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 265. CHINA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 266. CHINA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 267. CHINA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 268. CHINA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 269. CHINA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 270. CHINA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 271. CHINA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 272. CHINA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 273. CHINA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 274. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 275. GERMANY RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 276. GERMANY RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 277. GERMANY RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 278. GERMANY RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 279. GERMANY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 280. GERMANY RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 281. GERMANY RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 282. GERMANY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 283. GERMANY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 284. GERMANY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 285. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 286. JAPAN RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 287. JAPAN RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 288. JAPAN RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 289. JAPAN RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 290. JAPAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 291. JAPAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 292. JAPAN RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 293. JAPAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 294. JAPAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 295. JAPAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 296. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 297. INDIA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 298. INDIA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 299. INDIA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 300. INDIA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 301. INDIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 302. INDIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 303. INDIA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 304. INDIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 305. INDIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 306. INDIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 307. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 319. FRANCE RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 320. FRANCE RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 321. FRANCE RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 322. FRANCE RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 323. FRANCE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 324. FRANCE RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 325. FRANCE RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 326. FRANCE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 327. FRANCE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 328. FRANCE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 329. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 330. CANADA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 331. CANADA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 332. CANADA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 333. CANADA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 334. CANADA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 335. CANADA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 336. CANADA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 337. CANADA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 338. CANADA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 339. CANADA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 340. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 341. ITALY RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 342. ITALY RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 343. ITALY RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 344. ITALY RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 345. ITALY RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 346. ITALY RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 347. ITALY RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 348. ITALY RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 349. ITALY RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 350. ITALY RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 351. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 352. AUSTRALIA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 353. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 354. AUSTRALIA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 355. AUSTRALIA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 356. AUSTRALIA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 357. AUSTRALIA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 358. AUSTRALIA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 359. AUSTRALIA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 360. AUSTRALIA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 361. AUSTRALIA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 362. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 363. SOUTH KOREA RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 364. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 365. SOUTH KOREA RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 366. SOUTH KOREA RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 367. SOUTH KOREA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 368. SOUTH KOREA RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 369. SOUTH KOREA RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 370. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 371. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 372. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 373. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 374. BRAZIL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 375. BRAZIL RNA THERAPY MARKET SIZE, BY RNA TYPE, 2018-2032 (USD MILLION)
TABLE 376. BRAZIL RNA THERAPY MARKET SIZE, BY MESSENGER RNA, 2018-2032 (USD MILLION)
TABLE 377. BRAZIL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, 2018-2032 (USD MILLION)
TABLE 378. BRAZIL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 379. BRAZIL RNA THERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 380. BRAZIL RNA THERAPY MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
TABLE 381. BRAZIL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 382. BRAZIL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 383. BRAZIL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILL

Companies Mentioned

The companies featured in this RNA Therapy market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Benitec Biopharma Limited
  • Biogen Inc.
  • BioNTech SE
  • Cartesian Therapeutics, Inc.
  • Cenix BioScience GmbH
  • Deep Genomics
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • MiNA Therapeutics Limited
  • Moderna, Inc.
  • NeuBase Therapeutics, Inc.
  • Nordic Nanovector ASA
  • Novartis AG
  • Novo Nordisk A/S
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics N.V.
  • Sanofi S.A.
  • Silence Therapeutics PLC
  • Sirnaomics, Inc.
  • Suzhou Abogen Biosciences Co., Ltd.
  • Triplet Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 22.68 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

RNA Interference Technology Market by Molecule Type, Route of Administration, Delivery Method, Application, End-User - Global Forecast 2026-2032 - Product Image

RNA Interference Technology Market by Molecule Type, Route of Administration, Delivery Method, Application, End-User - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
RNA Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

RNA Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
NGS-Based RNA-Sequencing - Global Strategic Business Report - Product Image

NGS-Based RNA-Sequencing - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2032 - Product Image

Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2032

  • Report
  • 180 Pages
  • Global
From
Next Generation RNA Therapeutics Market (2nd Edition) by Type of Modality, Type of Molecule, Target Indication, Route of Administration, Geographical Regions and Leading Players-Trends and Forecast Till 2035 - Product Image

Next Generation RNA Therapeutics Market (2nd Edition) by Type of Modality, Type of Molecule, Target Indication, Route of Administration, Geographical Regions and Leading Players-Trends and Forecast Till 2035

  • Report
  • 241 Pages
  • Global
From

About the RNA Therapy Market

RNA therapy is a form of gene therapy that uses RNA molecules to treat or prevent diseases. It is a type of genomics-based therapy that works by introducing genetic material into cells to modify their behavior. RNA therapy can be used to treat a variety of diseases, including cancer, neurological disorders, and infectious diseases. It has the potential to be used to treat genetic disorders, as well as to modify the expression of genes in order to improve the effectiveness of existing treatments. RNA therapy works by introducing genetic material into cells, which can then be used to modify the expression of genes. This can be done by introducing a gene that produces a therapeutic protein, or by introducing a gene that silences a gene that is causing a disease. RNA therapy can also be used to modify the expression of existing genes, which can be used to improve the effectiveness of existing treatments. RNA therapy is an emerging field of genomics-based therapy, and is being explored by a number of companies. Examples of companies in the RNA therapy market include Moderna, BioNTech, and Arcturus Therapeutics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.